Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Short Interest Down 17.5% in March

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) was the recipient of a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 121,000 shares, a decrease of 17.5% from the February 28th total of 146,700 shares. Based on an average daily volume of 322,600 shares, the short-interest ratio is currently 0.4 days. Currently, 0.7% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Several research firms have commented on SNSE. Oppenheimer raised their price objective on Sensei Biotherapeutics from $3.50 to $4.00 and gave the company an “outperform” rating in a research report on Friday, March 28th. HC Wainwright reiterated a “buy” rating and set a $4.00 target price on shares of Sensei Biotherapeutics in a report on Friday, March 28th.

Sensei Biotherapeutics Price Performance

Sensei Biotherapeutics stock opened at $0.37 on Thursday. Sensei Biotherapeutics has a 12-month low of $0.25 and a 12-month high of $1.94. The company has a market capitalization of $9.21 million, a price-to-earnings ratio of -0.31 and a beta of 0.16. The firm’s fifty day moving average price is $0.46 and its 200 day moving average price is $0.49.

Sensei Biotherapeutics (NASDAQ:SNSE) last announced its earnings results on Friday, March 28th. The company reported ($0.27) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.27). Analysts forecast that Sensei Biotherapeutics will post -1.17 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. XTX Topco Ltd increased its stake in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 351.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 62,903 shares of the company’s stock after buying an additional 48,977 shares during the period. XTX Topco Ltd owned about 0.25% of Sensei Biotherapeutics worth $31,000 at the end of the most recent reporting period. 10.50% of the stock is currently owned by hedge funds and other institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.